Moderna announced positive five-year follow-up results from its Phase 2b trial showing its melanoma vaccine candidate (intismeran autogene plus KEYTRUDA) reduced recurrence or death risk by 49% compared to KEYTRUDA alone. The company also expanded its partnership with CEPI to develop a Bundibugyo ebolavirus vaccine, with CEPI committing up to $50 million. Despite the positive news, Moderna's stock fell 2.78% to $45.88.

RTW Investments purchased 16,010,524 shares of Erasca for approximately $189.23 million in Q1 2026, with the position's value rising to $261.42 million by quarter-end. The clinical-stage biotech company, which develops oral inhibitors targeting the RAS/MAPK pathway for cancer treatment, has seen its stock surge 800% over the past year. The investment reflects confidence in Erasca's lead program ERAS-0015, which showed encouraging early data in KRAS-driven cancers, and the company's strong cash position of $408.5 million expected to fund operations into late 2028.

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

Therini Bio announced the first patient dosing in a Phase 1b trial of THN391, a novel anti-inflammatory monoclonal antibody targeting fibrin for diabetic macular edema treatment. The company also advanced THN622, a fibrin/VEGF bispecific antibody, as a potential new standard of care for retinal neurodegeneration. Initial trial data is expected in Q4 2026.

The article recommends three dividend stocks for long-term holding: Merck, which is preparing for Keytruda patent expiration with a robust pipeline of 50+ trials; Verizon, a stable telecom with growth drivers in fixed wireless access and AI infrastructure; and Equinix, a data center REIT benefiting from the booming AI industry with consistent dividend growth.

The S&P 500 rallied to new highs despite record-low consumer sentiment, hawkish Fed signals, and geopolitical tensions. The market is experiencing a broad rotation from mega-cap AI stocks to semiconductor suppliers, quantum computing names, and space-launch companies. Quantum computing stocks surged following a $2 billion Commerce Department investment, while chip suppliers and AI infrastructure plays outperformed. Yields retreated from recent highs, providing relief to equity multiples and enabling the rally to extend.

Oorja Bio, a new clinical-stage biopharmaceutical company, announced a $30 million Series A funding round from Westlake BioPartners to develop ORJ-001, a first-in-class peptide therapeutic for idiopathic pulmonary fibrosis (IPF). The company has received FDA IND clearance and plans to initiate Phase 2 clinical trials in 2026. ORJ-001 is designed to restore alveolar epithelial type 2 (AEC2) cell function to promote lung repair and reverse fibrosis, addressing a significant unmet medical need in IPF treatment.

Regeneron Pharmaceuticals' stock dropped 10.20% in premarket trading after its Phase 3 melanoma trial failed to meet its primary endpoint. While the high-dose fianlimab combination showed numerically higher progression-free survival (11.5 months vs 6.4 months), it missed statistical significance with a p-value of 0.0627. The company also announced a partnership with Telix Pharmaceuticals to develop radiopharmaceutical therapies.

Revolution Medicines' experimental pancreatic cancer drug daraxonrasib has generated significant demand from cancer centers following FDA approval of its expanded access program in May. The Phase 3 RASolute 302 trial showed the drug doubled overall survival to 13.2 months versus 6.7 months for standard chemotherapy. However, the company faces operational challenges managing the compassionate use process, and RVMD stock declined 3.47% despite the positive clinical results.

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

Erasca announced a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015, a pan-RAS molecular glue, in combination with Merck's pembrolizumab (KEYTRUDA®) for treating RAS-mutant solid tumors. The AURORAS-1 Phase 1 trial showed favorable safety, tolerability, and clinical responses at low doses. Merck will supply pembrolizumab at no cost to support the proof-of-concept study.